Below are the most recent publications written about "Glucagon-Like Peptide 1" by people in Profiles.
-
Shah J, Makwana B, Panchal K, Patel V, Patel T, Khadke S, Verma A, Vivekanandan S, Kong Y, Upadhyay J, Dani SS, Ramsey KM, Ganatra S, Ramsey DJ. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients With Type 2 Diabetes and Diabetic Retinopathy. Am J Ophthalmol. 2026 Aug; 288:131-142.
-
Meyer KB, McVeigh M, Chiara AN, Boss KC, Pomfret TC, Semmel K, Bacon R, Nicolas D, Clements K, Alper CJ, Lenz K. Real-world 6-month persistence, adherence, and effectiveness of GLP-1 medications for overweight and obesity in a Medicaid population. J Manag Care Spec Pharm. 2026 Mar; 32(3):271-280.
-
Brand K, Landry D, Mulhern J, Braden G. Semaglutide reverses the chronic myopathy of hyperkalemic periodic paralysis: a case report. BMC Nephrol. 2025 04 07; 26(1):179.
-
Fath AR, Aglan A, Maron MS, Phillips JS, Maron BJ, Rowin EJ. Cardiovascular outcomes of glucagon-like peptide-1 agonist in patients with obesity and hypertrophic cardiomyopathy. Int J Cardiol. 2025 05 01; 426:133082.
-
Chiang CH, Song J, Chi KY, Chang YC, Xanthavanij N, Chang Y, Hsia YP, Chiang CH, Ghamari A, Reynolds KL, Lin S, Xu XH, Neilan TG. Glucagon-like Peptide-1 Agonists Reduce Cardiovascular Events in Cancer Patients on Immune Checkpoint Inhibitors. Eur J Cancer. 2025 Feb 05; 216:115170.
-
Lim JJ, Sequeira-Bisson IR, Yip WCY, Lu LW, Miles-Chan JL, Poppitt SD. Intra-pancreatic fat is associated with high circulating glucagon and GLP-1 concentrations following whey protein ingestion in overweight women with impaired fasting glucose: A randomised controlled trial. Diabetes Res Clin Pract. 2024 Jan; 207:111084.
-
Lim JJ, Liu Y, Lu LW, Sequeira IR, Poppitt SD. No Evidence That Circulating GLP-1 or PYY Are Associated with Increased Satiety during Low Energy Diet-Induced Weight Loss: Modelling Biomarkers of Appetite. Nutrients. 2023 May 20; 15(10).
-
Al Rifai M, Vaughan EM, Abushamat LA, Lee M, Ramsey DJ, Gupta K, Navaneethan SD, Virani SS. Correlates of Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes Mellitus (from the Department of Veterans Affairs). Am J Cardiol. 2022 06 01; 172:7-10.
-
Gourgari E, Huerta-Saenz L, Tonyushkina KN, Rosolowsky ET, Guttmann-Bauman I. Use of glucagon-like peptide-1 receptor agonists for pediatric patients with obesity and diabetes: The providers' perspectives. Pediatr Diabetes. 2021 09; 22(6):872-875.
-
Bird GH, Fu A, Escudero S, Godes M, Opoku-Nsiah K, Wales TE, Cameron MD, Engen JR, Danial NN, Walensky LD. Hydrocarbon-Stitched Peptide Agonists of Glucagon-Like Peptide-1 Receptor. ACS Chem Biol. 2020 06 19; 15(6):1340-1348.